Cipher Pharmaceuticals Inc (TSE:CPH) (NASDAQ:CPHR) was upgraded by research analysts at Bloom Burton from a “hold” rating to a “buy” rating in a research note issued on Friday, May 12th.
CPH has been the topic of several other reports. CIBC boosted their price objective on shares of Cipher Pharmaceuticals from C$6.90 to C$7.00 in a report on Friday, March 3rd. TD Securities restated a “hold” rating and issued a C$4.75 price objective on shares of Cipher Pharmaceuticals in a report on Tuesday, May 2nd.
Cipher Pharmaceuticals (TSE CPH) traded up 0.18% on Friday, reaching $5.55. 17,420 shares of the company traded hands. The stock’s 50-day moving average is $5.31 and its 200-day moving average is $4.69. The stock’s market capitalization is $147.14 million. Cipher Pharmaceuticals has a 1-year low of $3.50 and a 1-year high of $7.35.
ILLEGAL ACTIVITY WARNING: “Cipher Pharmaceuticals Inc (CPH) Upgraded by Bloom Burton to “Buy”” was first posted by Community Financial News and is the property of of Community Financial News. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece of content can be viewed at https://www.com-unik.info/2017/06/17/cipher-pharmaceuticals-inc-cph-upgraded-at-bloom-burton-updated-updated-updated.html.
In other Cipher Pharmaceuticals news, Director Harold Morton Wolkin purchased 23,700 shares of the business’s stock in a transaction on Wednesday, May 17th. The shares were bought at an average cost of C$5.45 per share, for a total transaction of C$129,165.00. Also, insider John Mull purchased 5,000 shares of the business’s stock in a transaction on Tuesday, June 13th. The shares were acquired at an average price of C$5.55 per share, for a total transaction of C$27,750.00. Insiders have acquired 87,900 shares of company stock worth $485,425 over the last quarter.
About Cipher Pharmaceuticals
Cipher Pharmaceuticals Inc is a specialty pharmaceutical dermatology company. The Company has a portfolio of commercial and late-stage products. It operates in the specialty pharmaceuticals segment. It acquires products and compounds for treatment of various medical needs. Its commercial product portfolio includes ABSORICA; SITAVIG; NUVAIL; BIONECT; CLN8; INOVA; PRO:12 MOUSSE; AL12; LOTION UMECTA; ACLARO; EPURIS; VANIQA; ACTIKERALL; BETEFLAM; LIPOFEN; CONZIP, and DURELA.
What are top analysts saying about Cipher Pharmaceuticals Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Cipher Pharmaceuticals Inc and related companies.